CAPN3 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P20807 |
---|
Gene ID | 825 |
---|---|
Other Names | Calpain-3, Calcium-activated neutral proteinase 3, CANP 3, Calpain L3, Calpain p94, Muscle-specific calcium-activated neutral protease 3, New calpain 1, nCL-1, CAPN3, CANP3, CANPL3, NCL1 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CAPN3 (HGNC:1480) |
---|---|
Synonyms | CANP3, CANPL3, NCL1 |
Function | Calcium-regulated non-lysosomal thiol-protease. Proteolytically cleaves CTBP1 at 'His-409'. Mediates, with UTP25, the proteasome-independent degradation of p53/TP53 (PubMed:23357851, PubMed:27657329). |
Cellular Location | Cytoplasm. Nucleus, nucleolus |
Tissue Location | Isoform I is skeletal muscle specific. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Calpain, a heterodimer consisting of a large and a small subunit, is a major intracellular protease, although its function has not been well established. This gene encodes a muscle-specific member of the calpain large subunit family that specifically binds to titin. Mutations in this gene are associated with limb-girdle muscular dystrophies type 2A.
References
Charlton, R., et al. Neuromuscul. Disord. 19(7):449-457(2009)Moretti, D., et al. Carcinogenesis 30(6):960-967(2009)Enjuanes, A., et al. Cancer Res. 68(24):10178-10186(2008)Beckmann, J.S., et al. Neuromuscul. Disord. 18(12):913-921(2008)Shirafuji, T., et al. Rinsho Shinkeigaku 48(9):651-655(2008)Diaz, B.G., et al. J. Biol. Chem. 279(26):27656-27666(2004)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.